{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '6.8.', 'Contraceptive Requirements', '52', '6.9.', 'Treatment Compliance', '52', '6.10.', 'Alcohol Restrictions', '52', '7.', 'STUDY ASSESSMENTS', '52', '7.1.', 'Screening/Baseline Assessments', '52', '7.1.1.', 'Patient Education Module', '53', '7.1.2.', 'Inhibitor Status', '53', '7.1.3.', 'FibroScan or FibroTest/APRI', '53', '7.2.', 'Efficacy Assessments', '53', '7.2.1.', 'Electronic Diary', '54', '7.3.', 'Pharmacodynamic Assessments', '55', '7.3.1.', 'Antithrombin Activity', '55', '7.3.2.', 'Thrombin Generation', '55', '7.3.3.', 'Exploratory Analyses', '55', '7.4.', 'Pharmacokinetic Assessments', '55', '7.5.', 'Safety Assessments', '56', '7.5.1.', 'Vital Signs', '56', '7.5.2.', 'Weight and Height', '56', '7.5.3.', 'Physical Examination', '56', '7.5.4.', 'Electrocardiogram', '57', '7.5.5.', 'Clinical Laboratory Assessments', '57', '7.5.5.1.', 'Additional Laboratory Assessments', '59', '7.5.5.2.', 'Immunogenicity', '60', '7.5.6.', 'Adverse Events', '60', '7.5.6.1.', 'Definitions', '60', '7.5.6.2.', 'Eliciting and Recording Adverse Events', '63', '7.5.6.3.', 'Serious Adverse Events and Adverse Events of Special Interest Require', 'Immediate Reporting to Sponsor/Designee', '64', '7.5.6.4.', 'Sponsor Safety Reporting to Regulatory Authorities', '64', '7.5.6.5.', 'Serious Adverse Event Notification to the Institutional Review', 'Board/Independent Ethics Committee', '64', '7.5.6.6.', 'Pregnancy Reporting', '64', '7.5.6.7.', 'Overdose Reporting', '65', 'Property of the Sanofi Group - strictly confidential', '19', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '7.5.6.8.', 'Guidelines for Reporting Product Complaints/Medical Device Incidents', '(Including Malfunctions)', '65', '7.6.', 'Other Assessments', '65', '7.6.1.', 'Patient-reported Outcomes', '65', '7.6.1.1.', 'HRQOL Instruments: Haem-A-QOL and Haemo-QOL', '65', '7.6.1.2.', 'TSQM-9', '66', '7.6.1.3.', 'HAL', '66', '7.6.1.4.', 'EQ-5D-5L', '66', '7.6.2.', 'Weight-adjusted Consumption of Factor Concentrates', '66', '7.6.3.', 'HJHS', '66', '8.', 'STATISTICS', '66', '8.1.', 'Determination of Sample Size', '67', '8.2.', 'Statistical Methodology', '67', '8.2.1.', 'Populations to be Analyzed', '67', '8.2.2.', 'Examination of Subgroups', '67', '8.2.3.', 'Handling of Missing Data', '67', '8.2.4.', 'Baseline Evaluations', '68', '8.2.5.', 'Efficacy Analyses', '68', '8.2.5.1.', 'Primary Endpoint', '68', '8.2.5.2.', 'Secondary Endpoints', '69', '8.2.5.3.', 'Exploratory Endpoints', '69', '8.2.6.', 'Pharmacodynamic Analysis', '69', '8.2.7.', 'Pharmacokinetic Analysis', '69', '8.2.8.', 'Safety Analyses', '69', '8.2.9.', 'Immunogenicity Analysis', '70', '8.2.10.', 'Interim Analysis', '70', '9.', 'STUDY ADMINISTRATION', '70', '9.1.', 'Ethical and Regulatory Considerations', '70', '9.1.1.', 'Informed Consent Process', '70', '9.1.2.', 'Ethical Review', '71', '9.1.3.', 'Study Documentation, Confidentiality, and Records Retention', '71', '9.1.4.', 'End of the Study', '71', '9.1.5.', 'Discontinuation of the Clinical Study', '71', 'Property of the Sanofi Group - strictly confidential', '20', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}